Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: A double-blind, randomised parallel study

European Journal of Cancer

Volumn 40, Issue 8, 2004, Pages 1188-1192

  Minegishi, Y ^a   Ohmatsu, H ^a   Miyamoto, T ^a   Niho, S ^a   Goto, K ^a   Kubota, K ^a   Kakinuma, R ^a   Kudoh, S ^b   Nishiwaki, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

5 HT3 receptor antagonist; Antiemetics; Chemotherapy; Cisplatin; Delayed emesis; Dopamine receptor antagonist; Droperidol; Granisetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; DROPERIDOL; GRANISETRON; PLACEBO;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GAIT DISORDER; HEADACHE; HICCUP; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOTION SICKNESS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RISK FACTOR; SOMNOLENCE; TREATMENT FAILURE; TREMOR; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOUBLE-BLIND METHOD; DROPERIDOL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 1942424090     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.01.027     Document Type: Article

References (19)

1. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The granisetron study group. Eur. J. Cancer. 26(Suppl. 1):1990;s33-s36.
2. Warr D., Willan A., Fine S.et al. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J. Natl. Cancer Inst. 83:1991;1169-1173.
3. Heron J.F., Goedhals L., Jordaan J.P.et al. Oral granisetron alone and in combination with dexamethasone. a double-blind randomised comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group Ann. Oncol. 5:1994;579-584.
4. Smith D.B., Newlands E.S., Rustin G.J.et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 338:1991;487-490.
5. Roila F., Tanato M., Cognetti F.et al. Prevention of cisplatin-induced emesis. a double-blind multicenter randomised crossover study comparing ondansetron and and ondansetron plus dexamethasone J. Clin. Oncol. 9:1991;675-678.
6. The Italian Group for Antiemetic Research Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med. 332:1995;1-5.
7. Kelley S.L., Braun T.J., Meyer T.J.et al. Trial of droperidol as an antiemetic in cisplatin chemotherapy. Cancer Treat Rep. 70:1986;469-472.
8. Sridhar K.S., Donnelly E. Combination antiemetics for cisplatin chemotherapy. Cancer. 61:1988;1508-1517.
9. Aapro M.S., Froidevaux P., Roth A.et al. Antiemetic efficacy of droperidol or metoclopramide combined with dexamethasone and diphenhydramine. Randomized open parallel study. Oncology. 48:1991;116-120.
10. Herrstedt J., Sigsgaard T., Boesgaard ?.et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N. Engl. J. Med. 328:1993;1076-1080.
11. Herrstedt J., Sigsgaard T., Handberg J.et al. Randomized, double-blind comparison of ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J. Clin. Oncol. 15:1997;1690-1696.
12. Navari R.M., Madajewicz S., Anderson N.et al. Oral ondansetron for the control of cisplatin-induced delayed emesis. a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo J. Clin. Oncol. 13:1995;2408-2416.
13. Gebbia V., Testa A., Valenza R.et al. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. Cancer. 76:1995;1821-1828.
14. Goedhals L., Heron J.F., Kleisbauer J.P.et al. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy. a double-blind, placebo-controlled, comparative study Ann. Oncol. 9:1998;661-666.
15. Tukada H., Hirose T., Yokoyama Y.et al. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur. J. Cancer. 37:2001;2398-2404.
16. The Italian Group for Antiemetic Research Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J. Clin. Oncol. 15:1997;124-130.
17. Latreille J., Pater J., Johnston D.et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trial Group. J. Clin. Oncol. 16:1998;1174-1178.
18. Campos D., Pereira J.R., Reinhardt R.R.et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 19:2001;1759-1767.
19. Navari R., Reinhardt R., Gralla R.J.et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N. Engl. J. Med. 340:1999;190-195.